Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study

Susan M. Domchek, Sophie Postel-Vinay, Seock Ah Im, Yeon Hee Park, Jean Pierre Delord, Antoine Italiano, Jerome Alexandre, Benoit You, Sara Bastian, Matthew G. Krebs, Ding Wang, Saiama N. Waqar, Mark Lanasa, Joon Rhee, Haiyan Gao, Vidalba Rocher-Ros, Emma V. Jones, Sakshi Gulati, Anna Coenen-Stass, Iwanka KozarewaZhongwu Lai, Helen K. Angell, Laura Opincar, Pia Herbolsheimer, Bella Kaufman

Research output: Contribution to journal › Article › peer-review

192 Scopus citations

Fingerprint

Dive into the research topics of 'Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study'. Together they form a unique fingerprint.

Medicine & Life Sciences